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ABSTRACT  
Patient characteristics associated with hypoglycaemia frequency during insulin glargine 
100 U/mL (Gla-100) titration and clinical outcomes at Week 24 were examined using 
participant-level data from 16 treat-to-target trials of people with type 2 diabetes mellitus 
inadequately controlled with oral antidiabetes drugs initiating Gla-100 (n=3549). 
Hypoglycaemia (plasma glucose <3.9 mmol/L or severe) during the first 8 weeks of 
titration was stratified by number of events (0, 1-3, and ≥4), resulting in 72.5%, 20.6%, 
and 6.9% of participants in each group, respectively. Glycaemic, body weight, and 
insulin dose changes from baseline to Weeks 12 and 24 were analysed. Hypoglycaemia 
was more common in participants with lower BMI and fasting C-peptide, and with 
sulfonylurea treatment. Glycaemic outcomes at Week 24 were similar in each 
hypoglycaemia group, despite the Week 24 mean daily dose and dose increase for Gla-
100 being highest in participants without hypoglycaemia, and lowest in those 
experiencing ≥4 events. Hypoglycaemia risk during Gla-100 titration mainly depends on 
patient characteristics and sulfonylurea use and may delay dose titration, but apparently 
has little effect on short-term glycaemic control in a clinical trial setting.  
 
KEYWORDS 
Type 2 diabetes mellitus, hypoglycaemia, insulin initiation, insulin glargine, C-peptide, 
clinical trial  
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is usually treated with diet and lifestyle modification 
followed by oral antidiabetes drugs (OADs), but many patients eventually require basal 
insulin to control blood glucose and reach glycaemic targets.1 Early initiation of basal 
insulin is more clinically beneficial and cost-effective than delaying until failure of three 
OADs2,3 and is recommended by international guidelines—especially in people with 
severe hyperglycaemia.1 
Insulin secretagogues and all forms of insulin therapy increase the risk of 
hypoglycaemia. Clinical outcomes and hypoglycaemia risk following initiation of basal 
insulin therapy vary depending on a patient’s pre-existing OAD regimen.4,5 Therefore, 
when initiating basal insulin therapy, greater insight into how patient characteristics and 
concurrent OADs may influence treatment efficacy and risk of hypoglycaemia would 
have clinical utility. The objective of this post-hoc, participant-level analysis was to 
compare baseline patient characteristics and clinical outcomes at Weeks 12 and 24, 
relative to the number of hypoglycaemia events reported during the first 8 weeks of 
forced insulin glargine 100 U/mL (Gla-100) titration when added to OAD therapy as a 
treat-to-target concept for ≥24 weeks in people with T2DM. 
 
METHODS 
Study design and patient selection 
Participant-level data were collected from randomised controlled trials of ≥24-weeks’ 
duration including insulin-naive people with T2DM inadequately controlled on OADs. All 
trials were conducted by Sanofi between 2000 and 2015. Studies using a forced titration 
algorithm (predominantly once-weekly dose adjustment by 2-8 U/day based on patient’s 
self-measured blood glucose) targeting fasting plasma glucose (FPG) ≤5.6 mmol/L 
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(≤100 mg/dL) and with at least one arm initiating Gla-100 (starting dose 10 U/day or 0.2 
U/kg) were considered; 16 studies fulfilled these criteria.6 
 
Endpoints 
As hypoglycaemia risk is generally low in insulin-naive people with T2DM, 
hypoglycaemia groups were classified as 0, 1-3, or ≥4 events per patient during the first 
8 weeks of treatment with Gla-100 (forced titration period). Hypoglycaemia was defined 
as ‘confirmed’ by a plasma glucose level of <3.9 mmol/L (<70 mg/dL), or ‘severe’ as 
hypoglycaemia requiring external assistance. Efficacy endpoints included change in 
glycated haemoglobin A1c (HbA1c), FPG, insulin dose, weight, and BMI from baseline to 
Weeks 12 and 24. Results were analysed for all patients and by concomitant OAD use 
(metformin, sulfonylurea, and metformin plus sulfonylurea). 
 
Statistical analysis 
Standardised, patient-level data were pooled from the studies. Analyses used 
descriptive statistics, and results are shown as mean (standard deviation) unless stated 
otherwise. All differences are numerical; statistical significance testing was not 
performed. 
 
RESULTS 
Patient characteristics 
Of 3549 participants (metformin: n=623; sulfonylurea: n=906; metformin plus 
sulfonylurea: n=1624; other: n=396), 2573 (72.5%) had no hypoglycaemia, 732 (20.6%) 
reported 1-3 hypoglycaemia events, and 244 (6.9%) reported ≥4 hypoglycaemia events 
during the first 8 weeks. Supplementary Table S1 shows baseline patient 
characteristics, stratified by hypoglycaemia frequency. 
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Patients without hypoglycaemia had the highest HbA1c at baseline. Patients 
experiencing ≥4 hypoglycaemia events had lower mean weight and C-peptide levels at 
baseline vs those experiencing ≤3 events. The number of hypoglycaemia events in the 
first 8 weeks diminished in all OAD subgroups with increasing baseline BMI and fasting 
C-peptide (Supplementary Tables S2 and S3). 
 
Clinical Outcomes 
Discontinuation rates 
Overall, 129 study participants (3.6%) discontinued treatment during the first 8 weeks, 
and another 232 (6.5%) later in the course of the study. For each study period, 
discontinuation rate was not found to be associated with the number of hypoglycaemia 
events during titration. 
 
Efficacy outcomes by hypoglycaemia events 
Changes in mean HbA1c and FPG from baseline to Week 24 were similar across all 
hypoglycaemia subgroups (Figure 1 and S2A). A higher proportion of patients 
experiencing ≥1 hypoglycaemia event during titration reached target HbA1c <7.0% (<53 
mmol/mol) or target FPG (≤5.6 mmol/L) levels at Weeks 12 and 24 vs those 
experiencing no hypoglycaemia events (Figure S1 and S2B).  
  
Glycaemic outcomes by concomitant OAD therapy are provided in Table S4. More 
people with T2DM in each OAD subgroup reached the target HbA1c <7.0% relative to an 
increasing number of hypoglycaemia events during titration, with the exception of those 
receiving metformin, of whom fewer reported ≥4 hypoglycaemia events (38.5%) vs 0 and 
1-3 events (55.3% and 69.3%, respectively); an outcome which might have been 
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influenced by the small size of this group, who had the lowest BMI and were likely to be 
more insulin sensitive. 
 
Basal insulin titration 
At similar baseline Gla-100 doses, dose increment over time differed when analysed by 
hypoglycaemia frequency (Figure 2A). Gla-100 dose increments were lower, and slower 
to rise, among participants experiencing hypoglycaemia vs those who did not. The mean 
daily Gla-100 dose at Week 24 was highest in those with no hypoglycaemia (0.47 [0.26] 
U/kg) and lowest in people experiencing ≥4 hypoglycaemia events (0.29 [0.14] U/kg) 
(Figure 2B). Analysed by OAD subgroup, study participants experiencing ≥4 
hypoglycaemia events recorded the smallest increase in insulin dose, regardless of the 
concomitant OAD (Table S4). 
 
Severe and non-severe hypoglycaemia 
During titration (Weeks 0-8) and throughout the continuing study period (Weeks 9-24) 
0.9% and 1.2% of participants, respectively, reported a severe hypoglycaemia event. 
Participants with no non-severe hypoglycaemia during titration also reported no severe 
hypoglycaemia during this period; only 0.7% of this group reported a severe event and 
19.5% a non-severe event in Weeks 9-24 (Table S4). A higher incidence and event rate 
of severe hypoglycaemia was observed in participants with 1-3 or ≥4 non-severe 
hypoglycaemia events both during titration and later in the course of the study. Similarly, 
event rates for non-severe hypoglycaemia were highest in participants with ≥4 non-
severe hypoglycaemia during titration both during first 8 weeks and later in the course of 
the study (Table S4). 
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Body weight and BMI 
Mean body weight and BMI at baseline differed considerably between hypoglycaemia 
groups (Table S1): mean weight change from baseline to Week 24 was 1.8 (3.7) kg in 
those not experiencing hypoglycaemia, 2.2 (3.5) kg in those experiencing 1-3 
hypoglycaemia events, and 1.9 (3.4) kg in those experiencing ≥4 hypoglycaemia events.  
Weight change in each group did not appear to be associated with the final Gla-100 
dose, but was associated with concomitant OAD therapy (Table S4). Weight gain 
ranged from 0.7 kg with metformin and no hypoglycaemia, to 3.9 kg with sulfonylurea 
and ≥4 hypoglycaemia events. 
 
DISCUSSION 
In recognition of the heterogeneity of the T2DM population at insulin initiation, this post-
hoc analysis was undertaken to identify patient characteristics that might influence the 
response to basal insulin in terms of hypoglycaemia risk during titration.  
Incidence of hypoglycaemia in this population of insulin-naive people with T2DM was 
within expected boundaries, with 27.5% of participants reporting hypoglycaemia (non-
severe or severe); only 6.9% of those had ≥4 events during the 8-week titration period. 
Higher risk of hypoglycaemia during titration was also associated with a continued higher 
risk of non-severe and severe events throughout the later study period, indicating the 
importance of avoiding or reducing hypoglycaemia early during titration to minimise long-
term risk. Our analysis has identified patient characteristics that may predispose to an 
increased risk of hypoglycaemia during insulin titration. These are a lower body weight 
and BMI at the time of insulin initiation, and low levels of fasting C-peptide, 
characterising an insulin-sensitive group who may require a lower dose of basal insulin 
to reach glycaemic targets, and therefore might need a more tailored titration strategy 
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and/or more vigilance regarding hypoglycaemia events. Since glutamic-acid-
decarboxylase antibodies were not measured in these studies, it is also possible that the 
lean, more C-peptide-deficient subgroup included a subpopulation with latent 
autoimmune diabetes in adults (LADA), subsumed within the heterogeneous T2DM 
population.7 Our results add to the existing evidence of the increased risk of 
hypoglycaemia with concomitant sulfonylurea use,4,8 here shown specifically for the 
titration period. In addition, it shows that people with greater insulin resistance may 
benefit from the addition of Gla-100 to an oral regimen consisting of metformin, while 
avoiding sulfonylurea-based regimens and/or withdrawing sulfonylurea when basal 
insulin is initiated. This finding supports the timely introduction of basal insulin to 
metformin monotherapy, particularly for patients with higher HbA1c levels on this 
therapy, and indirectly suggests that additional drugs (which may include another 
injectable) may be needed in some individuals to reach target HbA1c. 
The number of hypoglycaemia events during the 8-week titration period had little effect 
on short-term glycaemic outcomes (24 weeks); however it affected overall insulin-dose 
titration as expected. At Week 24, the difference in mean HbA1c across the three 
hypoglycaemia-frequency groups was <0.2%, but final mean basal insulin doses ranged 
from 0.29 (0.14) to 0.47 (0.26) U/kg. The analysis of all groups by number of 
hypoglycaemia events during titration or concomitant OAD showed that, in general, the 
highest percentages of people who reached the target of HbA1c <7.0% at Week 24 were 
those who received metformin (without sulfonylurea) and who had increasing 
hypoglycaemia risk during the first 8 weeks with Gla-100. This finding suggests that 
early occurrence of hypoglycaemia during titration does not necessarily prevent patients 
from achieving short- or longer-term glycaemic targets; however, these outcomes have 
been observed in a clinical research setting, where participants received a monitored 
forced insulin titration to achieve the predefined FPG target. As reported previously,9 it is 
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also uncertain whether early hypoglycaemia during Gla-100 titration and recurrent 
hypoglycaemia later in the course of the studies induce a negative effect on treatment 
satisfaction or quality-of-life as such data were not systematically measured. Our 
findings, however, showed that people with hypoglycaemia during titration continue to 
experience considerably more severe and non-severe hypoglycaemia events than those 
who have no hypoglycaemia during titration. In addition, it is unclear how these results 
transfer to real-world use, as in daily practice a forced insulin titration period is not 
standard practice, and daily insulin doses are generally lower than in clinical trials. 
Therefore, in real-world practice, early and recurrent hypoglycaemia after insulin 
initiation might have a significant negative impact on mid- and long-term glycaemic 
control as fear of (and experienced) hypoglycaemia often associates with insufficient 
insulin titration, reduced adherence and compliance to insulin treatment, and higher 
discontinuation rates of insulin treatment than observed in randomized controlled 
trials.10-13 
 
A limitation of this post-hoc analysis is that it describes observations associated with 
retrospectively defined hypoglycaemia subgroups and by necessity has used a 
descriptive analysis; it therefore cannot demonstrate any causality of these associations. 
Confounding factors other than BMI, weight, or fasting C-peptide level may also have 
contributed to the difference in hypoglycaemia risk during Gla-100 titration.  
 
In summary, the present retrospective analysis of hypoglycaemia risk in a large sample 
of people with T2DM initiating Gla-100 after inadequate glycaemic control on oral 
therapy has identified people who required or received different insulin doses to reach a 
similar level of glycaemic control, but who also differed considerably in characteristics 
associated with hypoglycaemia risk during titration. Hypoglycaemia events (PG <3.9 
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mmol/L or severe) were more likely to occur when Gla-100 was added to concomitant 
sulfonylurea (without metformin) and in people with low body weight/BMI or low levels of 
fasting C-peptide before commencing basal insulin.  
Further prospective studies in a real-world setting are required to examine whether the 
patient characteristics identified in the present analysis can be confirmed. 
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Tables and Figures: 
Figure 1. Mean HbA1c at baseline and Weeks 12 and 24 after Gla-100 initiation. 
 
Gla-100, insulin glargine 100 U/mL; HbA1c, glycated haemoglobin A1c.  
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Figure 2. (A.) Change in Gla-100 dose over study duration and (B.) mean dose at 
baseline and Weeks 12 and 24, stratified by number of hypoglycaemia events occurring 
during forced Gla-100 titration (Weeks 0-8). 
 
Gla-100, insulin glargine 100 U/mL. 
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SUPPLEMENTARY INFORMATION 
Table S1. Sociodemographic and baseline characteristics of participants with T2DM 
stratified by number of hypoglycaemia events during Gla-100 titration (Weeks 0-8). 
Characteristic Overall population 
 Number of hypoglycaemia events, weeks 0-8† 
 
0 
n=2,573 
1-3 
n=732 
≥4 
n=244 
Age, years‡ 57.7 (19.6-86.2) 58.3 (26.7-84.7) 59.1 (31.2-77.0) 
Male, n (%) 1,385 (53.8) 384 (52.5) 125 (51.2) 
T2DM duration, years‡  7.0 (0.0-50.0) 8.3 (0.5-45.0) 8.0 (0.8-40.0) 
Weight, kg 87.7 (18.5) 83.3 (17.4) 77.6 (14.7) 
BMI, kg/m2 31.0 (5.3) 29.6 (4.9) 28.4 (4.5) 
HbA1c, % 8.8 (1.1) 8.6 (1.0) 8.5 (1.0) 
HbA1c, mmol/mol 72.7 (9.1) 70.5 (8.2) 69.4 (8.2) 
FPG, mmol/L 10.8 (3.0) 10.4 (2.9) 10.3 (3.4) 
FPG, mg/dL 194 (54) 187 (52) 185 (61) 
Insulin dose day 1, U/kg 0.16 (0.07) 0.16 (0.08) 0.19 (0.11) 
Insulin dose, U/day 13.3 (5.7) 13.0 (5.8) 14.4 (8.3) 
Fasting C-peptide, nmol/L 1.21 (0.64) 1.04 (0.56) 0.95 (0.54) 
† Hypoglycaemia events were defined as confirmed (PG <3.9 mmol/L [<70 mg/dL]) or severe (any event 
requiring third-party assistance). ‡Age and diabetes duration are presented as median (range). 
Other data are presented as mean (SD).  
FPG, fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; HbA1c, glycated haemoglobin A1c; 
PG, plasma glucose; SD, standard deviation; T2DM, type 2 diabetes mellitus.  
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Table S2. Baseline BMI by number of hypoglycaemia events during Gla-100 titration 
(Weeks 0-8) and concomitant OAD use. 
OAD group 
Baseline BMI (kg/m2) by number of hypoglycaemia events 
during weeks 0-8 
0 1-3 ≥4 
MET 31.8 (5.7) 29.3 (4.9) 26.7 (4.6) 
SU 29.6 (5.2) 27.7 (4.6) 26.6 (3.9) 
MET+SU 31.4 (5.0) 30.4 (4.8) 29.1 (4.4) 
Data are shown as mean (SD). 
Gla-100, insulin glargine 100 U/mL; MET, metformin; OAD, oral antidiabetes drug; SD, standard deviation; 
SU, sulfonylurea. 
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Table S3: Baseline C-peptide level by number of hypoglycaemia events during Gla-100 
titration (Weeks 0-8) with concomitant OAD use.  
OAD group 
Baseline C-peptide (nmol/L) by number of hypoglycaemia 
events during weeks 0-8 
0 1-3 ≥4 
MET 1.11 (0.47) 0.75 (0.33) 0.46 (0.24) 
SU 1.26 (0.77) 1.03 (0.63) 0.88 (0.88) 
MET+SU 1.20 (0.57) 1.08 (0.53) 1.00 (0.51) 
Data are shown as mean (SD).  
Gla-100, insulin glargine 100 U/mL; MET, metformin; OAD, oral antidiabetes drug; SD, standard deviation; 
SU, sulfonylurea. 
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Table S4: Clinical outcomes stratified by number of hypoglycaemia events during Gla-
100 titration (Weeks 0-8) and concomitant OAD use. 
Outcome 
Concomitant 
OAD 
Number of hypoglycaemia events  
during weeks 0-8 
0 1-3 ≥4 
HbA1c  
Week 12, % 
MET 
MET+SU 
SU 
7.3 (1.0) 
7.4 (0.9) 
7.8 (1.2) 
6.9 (0.9) 
7.1 (0.8) 
7.5 (1.1) 
7.4 (0.9) 
7.0 (0.7) 
7.4 (1.2) 
HbA1c  
Week 24, % 
MET 
MET+SU 
SU 
7.0 (1.0) 
7.1 (0.9) 
7.6 (1.2) 
6.8 (1.0) 
6.9 (0.8) 
7.4 (1.1) 
7.5 (1.0) 
6.9 (0.7) 
7.4 (1.2) 
Patients with  
HbA1c <7.0%  
Week 24, n (%) 
MET 
MET+SU 
SU 
284 (55.3) 
457 (45.2) 
196 (30.1) 
52 (69.3) 
220 (54.2) 
61 (37.2) 
5 (38.5) 
92 (59.4) 
21 (38.9) 
FPG 
Week 12, mmol/L  
MET 
MET+SU 
SU 
6.7 (2.1) 
6.9 (2.1) 
7.0 (2.2) 
5.9 (2.4) 
6.4 (1.8) 
6.2 (2.0) 
5.3 (1.1) 
6.2 (2.1) 
6.0 (2.3) 
FPG  
Week 24, mmol/L 
MET 
MET+SU 
SU 
6.3 (1.9) 
6.7 (2.1) 
6.9 (2.3) 
6.0 (2.5) 
6.4 (1.9) 
6.2 (1.9) 
6.4 (2.4) 
6.1 (1.9) 
6.0 (1.5) 
Patients with  
FPG ≤5.6 mmol/L  
Week 24, n (%) 
MET 
MET+SU 
SU 
200 (40.5) 
295 (29.8) 
289 (28.4) 
39 (54.2) 
151 (37.4) 
73 (44.0) 
5 (38.5) 
66 (45.8) 
25 (45.5) 
Insulin dose  
Week 12, U/kg 
MET 
MET+SU 
SU 
0.46 (0.22) 
0.39 (0.20) 
0.40 (0.20) 
0.37 (0.16) 
0.31 (0.16) 
0.35 (0.19) 
0.26 (0.13) 
0.25 (0.13) 
0.33 (0.11) 
Insulin dose  
Week 24, U/kg 
MET 
MET+SU 
SU 
0.53 (0.28) 
0.45 (0.26) 
0.45 (0.24) 
0.38 (0.19) 
0.35 (0.18) 
0.37 (0.21) 
0.27 (0.08) 
0.28 (0.15) 
0.32 (0.13) 
Weight change  
Baseline to Week 24, kg 
MET 
MET+SU 
SU 
0.7 (3.9) 
1.8 (3.3) 
2.5 (3.8) 
1.2 (3.6) 
1.9 (3.2) 
3.3 (3.8) 
2.1 (2.6) 
1.4 (2.9) 
3.9 (4.0) 
Non-severe hypoglycaemia†  
Week 0-8, % people 
Week 9-24, % people 
Week 0-8, events/patient-year§ 
Week 9-24, events/patient-year§ 
All OADs  
0.0 
19.5 
0.0 
2.7 (0.1) 
 
20.6 
13.1 
10.4 (0.3) 
10.1 (0.6) 
 
6.9 
6.1 
43.7 (1.4) 
26.8 (1.7) 
Severe hypoglycaemia All OADs    
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Outcome 
Concomitant 
OAD 
Number of hypoglycaemia events  
during weeks 0-8 
0 1-3 ≥4 
Week 0-8, % people 
Week 9-24, % people 
Week 0-8, events/patient-year§ 
Week 9-24, events/patient-year§ 
 0.0 
0.7 
0.0 
0.03 (0.01) 
3.4 
2.3 
0.24 (0.07) 
0.10 (0.03) 
3.3 
3.3 
0.46 (0.21) 
0.51 (0.21) 
† plasma glucose <3.9 mmol/L (<70 mg/dL). § Mean (SE). 
Data are shown as mean (SD) unless otherwise specified. 
FPG, fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; MET, metformin; OAD, oral antidiabetes 
drug; PG, plasma glucose; SD, standard deviation; SU, sulfonylurea. 
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Figure S1: Percentage of people with T2DM and at target HbA1c 7.0% (53 mmol/mol), 
stratified by number of hypoglycaemia (PG <3.9 mmol/L [<70 mg/dL] or severe†) events 
during forced Gla-100 titration (Weeks 0-8). 
 
† Hypoglycaemia events were defined as confirmed (PG <3.9 mmol/L) or severe (any event requiring third-
party assistance).  
HbA1c, glycated haemoglobin A1c; PG, plasma glucose; T2DM, type 2 diabetes mellitus.  
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FIGURE S2. (A). Mean FPG at baseline, Weeks 12 and 24 and (B.) percentage of 
people with T2DM at target FPG 5.6 mmol/L (100 mg/dL) stratified by number of 
hypoglycaemia events (PG <3.9 mmol/L [<70 mg/dL] or severe†) during forced Gla-100 
titration (Weeks 0-8). 
 
† Hypoglycaemia events were defined as confirmed (PG <3.9 mmol/L) or severe (any event requiring third-
party assistance).  
FPG, fasting plasma glucose; PG, plasma glucose; T2DM, type 2 diabetes mellitus. 
